Skip to Main Content

Paper Details

Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.
J Clin Oncol
19
2022
Adults, Children, HGG, MAPK, MEK, Mitogen-Activated Protein Kinase, Patients, Selumetinib, Tumors, V600E, children, high-grade glioma, histiocytic disorders, hotspot, low-grade glioma, lymphomas, mitogen-activated protein kinase, patients, pediatric, pediatric cancers, pediatric tumors, plexiform neurofibroma, rhabdomyosarcoma, selumetinib, solid tumors, tumors
Author NameAffiliation
Todd A AlonzoKeck School of Medicine, University of Southern California
Todd A AlonzoKeck School of Medicine, University of Southern California
Nilsa C RamirezResearch Institute at Nationwide Children's Hospital
Elizabeth FoxSt Jude Children's Research Hospital
Douglas S HawkinsSeattle Children's Hospital and University of Washington
Katherine A JanewayDana-Farber Cancer Institute
Donald W ParsonsBaylor College of Medicine
Donald W ParsonsBaylor College of Medicine
  • 1 - 8

Datasets

Release 1.2